CN112004541A - 肠道外给药的免疫增强药物 - Google Patents

肠道外给药的免疫增强药物 Download PDF

Info

Publication number
CN112004541A
CN112004541A CN201980018034.4A CN201980018034A CN112004541A CN 112004541 A CN112004541 A CN 112004541A CN 201980018034 A CN201980018034 A CN 201980018034A CN 112004541 A CN112004541 A CN 112004541A
Authority
CN
China
Prior art keywords
optionally substituted
group
alkyl
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018034.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·哈恩
J·L·杰弗里
金莉霞
J·卡利夏克
K·V·劳森
M·R·莱莱蒂
J·J·卡拉昆内尔
J·P·帕沃尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcus Biosciences Inc
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CN112004541A publication Critical patent/CN112004541A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980018034.4A 2018-03-09 2019-03-08 肠道外给药的免疫增强药物 Pending CN112004541A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862641003P 2018-03-09 2018-03-09
US62/641,003 2018-03-09
US201862700548P 2018-07-19 2018-07-19
US62/700,548 2018-07-19
PCT/US2019/021300 WO2019173682A1 (en) 2018-03-09 2019-03-08 Parenterally administered immune enhancing drugs

Publications (1)

Publication Number Publication Date
CN112004541A true CN112004541A (zh) 2020-11-27

Family

ID=67846288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018034.4A Pending CN112004541A (zh) 2018-03-09 2019-03-08 肠道外给药的免疫增强药物

Country Status (8)

Country Link
US (1) US12433836B2 (OSRAM)
EP (1) EP3761993A4 (OSRAM)
JP (2) JP7417530B2 (OSRAM)
KR (1) KR102822181B1 (OSRAM)
CN (1) CN112004541A (OSRAM)
AU (1) AU2019231781B2 (OSRAM)
CA (1) CA3092585A1 (OSRAM)
WO (1) WO2019173682A1 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022237747A1 (zh) * 2021-05-11 2022-11-17 四川海思科制药有限公司 小分子cd73拮抗剂及其用途
WO2023241699A1 (zh) * 2022-06-17 2023-12-21 上海森辉医药有限公司 一种环戊基腺苷衍生物及其药物用途
CN117562915A (zh) * 2023-12-05 2024-02-20 中国药科大学 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
WO2025050491A1 (zh) * 2023-09-05 2025-03-13 厦门大学 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
CN120285176A (zh) * 2025-04-25 2025-07-11 谈高 抗CD73单抗联合Adora1抑制剂在治疗肠纤维化中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201805506YA (en) 2016-01-08 2018-07-30 Arcus Biosciences Inc Modulators of 5'-nucleotidase, ecto and the use thereof
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
EP3849992A4 (en) * 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US20230086099A1 (en) * 2020-01-30 2023-03-23 Ona Therapeutics, S.L. Combination therapy for treatment of cancer and cancer metastasis
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
AU2021292195A1 (en) 2020-06-17 2023-01-05 Arcus Biosciences, Inc. Crystalline forms of a CD73 inhibitor and uses thereof
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
WO2023076392A1 (en) 2021-10-26 2023-05-04 Southern Research Institute Development of novel clofarabine analogs for cancer therapy
CN120091809A (zh) * 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267710A1 (en) * 2016-01-08 2017-09-21 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
EP1259234B9 (en) 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
EP3518934A4 (en) * 2016-10-03 2020-06-24 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
JP7150712B2 (ja) 2016-11-18 2022-10-11 アーカス バイオサイエンシズ インコーポレイティド Ｃｄ７３媒介免疫抑制の阻害剤
EP3893891A4 (en) * 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267710A1 (en) * 2016-01-08 2017-09-21 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022237747A1 (zh) * 2021-05-11 2022-11-17 四川海思科制药有限公司 小分子cd73拮抗剂及其用途
WO2023241699A1 (zh) * 2022-06-17 2023-12-21 上海森辉医药有限公司 一种环戊基腺苷衍生物及其药物用途
WO2025050491A1 (zh) * 2023-09-05 2025-03-13 厦门大学 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
CN117562915A (zh) * 2023-12-05 2024-02-20 中国药科大学 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
CN120285176A (zh) * 2025-04-25 2025-07-11 谈高 抗CD73单抗联合Adora1抑制剂在治疗肠纤维化中的应用

Also Published As

Publication number Publication date
KR102822181B1 (ko) 2025-06-18
AU2019231781A1 (en) 2020-10-22
US20200405629A1 (en) 2020-12-31
EP3761993A4 (en) 2022-03-09
WO2019173682A1 (en) 2019-09-12
US12433836B2 (en) 2025-10-07
AU2019231781B2 (en) 2025-02-13
JP2021515775A (ja) 2021-06-24
CA3092585A1 (en) 2019-09-12
JP2023165998A (ja) 2023-11-17
KR20200130843A (ko) 2020-11-20
JP7417530B2 (ja) 2024-01-18
EP3761993A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7417530B2 (ja) 優先投与される免疫増強薬
JP7698677B2 (ja) ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用
CN112996509B (zh) 吡啶酮a2r拮抗剂
ES2953349T3 (es) Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
CN110049767B (zh) 腺苷5′-核苷酸酶的抑制剂
CN110636846B (zh) 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN110022881B (zh) Cd73介导的免疫抑制的抑制剂
KR20200128117A (ko) 아르기나아제 억제제
AU2019222747B2 (en) Dosing with an azolopyrimidine compound
US11633416B1 (en) Oral formulations of CD73 compounds
CN115942977A (zh) Cd73抑制剂的结晶形式及其用途
HK40043095A (en) Parenterally administered immune enhancing drugs
HK40073403A (zh) 胞外5’-核苷酸酶的调节剂及其用途
HK40055891B (zh) 吡啶酮a2r拮抗剂
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043095

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20201127

RJ01 Rejection of invention patent application after publication